ライフサイエンスコーパス: aliskiren

1 um creatinine in CNI groups was abolished by Aliskiren.

2 pproaches used toward the total synthesis of aliskiren.

3 shape of the first approved renin inhibitor, aliskiren.

4 t in principal cells, which was prevented by Aliskiren.

5 diet, receiving separate escalating doses of aliskiren.

6 not differ between participants treated with aliskiren (-0.33%; 95% CI, -0.68% to 0.02%) and placebo

7 were randomly assigned to receive once-daily aliskiren 150 mg (n=437), valsartan 160 mg (455), a comb

8 7), valsartan 160 mg (455), a combination of aliskiren 150 mg and valsartan 160 mg (446), or placebo

9 Aliskiren 150 mg is as effective as irbesartan 150 mg in

10 The antihypertensive effect of aliskiren 150 mg was comparable to that of irbesartan 15

11 Aliskiren 150, 300, and 600 mg effectively lowered both

12 lind treatment with once-daily oral doses of aliskiren (150, 300, or 600 mg), irbesartan 150 mg, or p

13 g per day), Tac (0.075 mg/kg per day), CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 w

14 Aliskiren 300 and 600 mg lowered mean sitting DBP signif

15 significantly more than either monotherapy (aliskiren 300 mg 9.0 mm Hg decrease, p<0.0001; valsartan

16 At week 8 endpoint, the combination of aliskiren 300 mg and valsartan 320 mg lowered mean sitti

17 ease were randomly assigned (1:1) to receive aliskiren 300 mg per day or placebo as an adjunct to ACE

18 , and body mass index >25 kg/m(2) to receive aliskiren 300 mg, losartan 100 mg, or their combination

19 shion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an

20 315 patients initially allocated to aliskiren, 315 allocated to amlodipine, and 617 allocate

21 318 patients were randomly assigned to aliskiren, 316 to amlodipine, and 620 to aliskiren plus

22 not differ between participants treated with aliskiren (-4.1 mm3; 95% CI, -6.27 to -1.94 mm3) and pla

23 ion, dose-dependent BP reduction occurs with aliskiren 75-300 mg once daily; at these doses, the safe

24 In total, 24.9% of patients receiving aliskiren (77 CV deaths, 153 HF rehospitalizations) and

25 d in the final efficacy analysis cohort (808 aliskiren, 807 placebo).

26 Moreover, drugs aliskiren (a renin inhibitor) and darunavir (an HIV-1 PR

27 Treatment with aliskiren (a renin inhibitor), but not hydralazine (a sm

28 Aliskiren, a direct renin inhibitor blocks these effects

29 Molecular modeling was used to develop aliskiren, a potent, low-molecular-weight, nonpeptide, d

30 betes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage o

31 We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy

32 ng the long-term renal protective effects of aliskiren and its effects on ventricular remodeling are

33 952, reflecting the higher pharmacy costs of aliskiren and losartan ($7769), which were partially off

34 08) and TAV (64.4% vs 57.5%; P = .13) in the aliskiren and placebo groups, respectively.

35 a tolerability profile similar to that with aliskiren and valsartan alone.

36 The combination of aliskiren and valsartan at maximum recommended doses pro

37 ention with the maximum recommended doses of aliskiren and valsartan, compared with each drug alone i

38 This study suggests that canagliflozin, aliskiren, and darunavir may induce profound effects tow

39 occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to place

40 Noninferiority was not shown for aliskiren as compared with enalapril.

41 e of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to re

42 isk of developing hypertension and diabetes, aliskiren-based or canagliflozin-based drug design again

43 nd diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg,

44 When added to an ARB, aliskiren blocks compensatory RAS activation and produce

45 iAng II synthesis was blocked by aliskiren but not by benazepril.

46 currently underway assessing the effects of aliskiren combined with an angiotensin receptor blocker

47 sion and coronary artery disease, the use of aliskiren compared with placebo did not result in improv

48 althy people with the potent renin inhibitor aliskiren exceeded responses seen previously with angiot

49 CyA + Aliskiren (25 mg/kg per day), or Tac + Aliskiren for 3 weeks.

50 These findings do not support the use of aliskiren for regression or prevention of progression of

51 2 months, the event rates were 35.0% for the aliskiren group (126 CV deaths, 212 HF rehospitalization

52 come occurred in 791 patients (33.8%) in the aliskiren group (hazard ratio vs. enalapril, 0.99; 95% C

53 3 m(2) per year (95% CI -2.9 to -3.3) in the aliskiren group and -3.0 mL/min/1.73 m(2) per year (-2.8

54 impairment/renal failure were higher in the aliskiren group compared with placebo.

55 l per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2

56 he trial (63 in the placebo group, 53 in the aliskiren group, 43 in the valsartan group, and 37 in th

57 ren plus amlodipine group, 45 (14%) from the aliskiren group, and 58 (18%) from the amlodipine group.

58 t groups (6.5+/-14.9/3.8+/-10.1 mm Hg in the aliskiren group; 5.5+/-15.6/3.7+/-10.7 mm Hg in the losa

59 ized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce

60 The Aliskiren in the Evaluation of Proteinuria in Diabetes (

61 determine the place of renin inhibition and aliskiren in the treatment of hypertension and related c

62 Aliskiren induced a remarkable dose-related renal vasodi

63 direct comparison studies, BP reduction with aliskiren is equivalent to commonly used antihypertensiv

64 Aliskiren is likely to be of most value in patients unco

65 Aliskiren is the first orally active inhibitor of renin

66 4.9-, 4.8-, and 5.8 g/m(2) reductions in the aliskiren, losartan, and combination arms, respectively;

67 Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safe

68 Our data suggest that Aliskiren may be used for the prevention of CNI nephroto

69 These results indicate that aliskiren may provide more complete and thus more effect

70 ing and were randomized to receive 300 mg of aliskiren (n = 305) or placebo (n = 308) taken orally da

71 were treated with a direct renin inhibitor, aliskiren (n = 7), or a diuretic, hydrochlorothiazide (n

72 as a low-sodium comparison and also received aliskiren on a high-sodium (200 mmol/d) diet.

73 The effect of aliskiren on receptor-bound renin and pro-renin is the s

74 s of the ALTITUDE trial showed no benefit of aliskiren on renal outcomes (doubling of serum creatinin

75 the ALTITUDE trial to analyse the effects of aliskiren on surrogate renal outcomes in all patients an

76 The absence of a benefit of aliskiren on the primary composite renal endpoint in the

77 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard ther

78 s, we administered the novel renin inhibitor aliskiren over a broad dose range to fat-fed LDL recepto

79 re different between hydrochlorothiazide and aliskiren (P = 0.006 pre/post x drug).

80 nts received combination therapy with 300 mg aliskiren plus 10 mg amlodipine.

81 ebo, 5 mg amlodipine plus placebo, or 150 mg aliskiren plus 5 mg amlodipine.

82 sure (>150 mm Hg) with a combination such as aliskiren plus amlodipine can be recommended.

83 drawal of 85 patients (14%) from the initial aliskiren plus amlodipine group, 45 (14%) from the alisk

84 llocated to amlodipine, and 617 allocated to aliskiren plus amlodipine were available for analysis.

85 to aliskiren, 316 to amlodipine, and 620 to aliskiren plus amlodipine.

86 -adjusted life years, and lifetime costs for aliskiren plus losartan versus losartan.

87 Reduction in LV mass with the combination of aliskiren plus losartan was not significantly different

88 ly assigned (1:1:2) to treatment with 150 mg aliskiren plus placebo, 5 mg amlodipine plus placebo, or

89 bited by candesartan and benazepril, whereas aliskiren produced complete inhibition.

90 In patients with hypertension, aliskiren produces dose-dependent blood pressure (BP) re

91 given with an angiotensin receptor blocker, aliskiren produces significant additional BP reduction i

92 double-blind, randomized, multicenter trial (Aliskiren Quantitative Atherosclerosis Regression Intrav

93 Two-week treatment with aliskiren (renin inhibitor) or losartan (AT1 antagonist)

94 sartan (ARB), benazepril (ACE inhibitor), or aliskiren (renin inhibitor).

95 Aliskiren showed no beneficial effect on hard renal outc

96 Aliskiren showed safety and tolerability comparable to t

97 oximately 300 mg once daily; at these doses, aliskiren shows placebo-like tolerability.

98 Aliskiren significantly decreased progression (hazard ra

99 Aliskiren suppresses PRA when given either as monotherap

100 first 6 months was significantly larger with aliskiren than with placebo (-2.5 mL/min/1.73 m(2), 95%

101 We compared the effect of aliskiren, the first orally active direct renin inhibito

102 The development of aliskiren, the first orally effective renin inhibitor, u

103 We estimated the cost-effectiveness of aliskiren to be $30,500 per quality-adjusted life year g

104 with chronic heart failure, the addition of aliskiren to enalapril led to more adverse events withou

105 In conclusion, adding aliskiren to losartan and optimal therapy in patients wi

106 We found that adding aliskiren to losartan increased time free of ESRD, life

107 ients with diabetic nephropathy, addition of aliskiren to losartan, 100 mg resulted in a 20% greater

108 ted, there was a greater benefit from adding aliskiren to natriuretic drugs than to other blockers of

109 The addition of aliskiren to standard therapy with renin-angiotensin sys

110 inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiorit

111 After aliskiren treatment, supine MSNA remained unchanged (69

112 morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes in Patients with He

113 Morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes in Patients With He

114 y in Heart Failure) or the ATMOSPHERE trial (Aliskiren Trial to Minimize Outcomes in Patients With He

115 up, 43 in the valsartan group, and 37 in the aliskiren/valsartan group), mainly due to lack of therap

116 1.73 m(2) per year, 95% CI -3.0 to -2.6 with aliskiren vs -3.1 mL/min/1.73 m(2) per year, 95% CI -3.3

117 These findings suggest that aliskiren was as effective as an angiotensin receptor bl

118 Aliskiren was as effective as losartan in promoting LV m

119 Aliskiren was as effective as losartan in reducing LV ma

120 Aliskiren was found to be effective either as monotherap

121 secondary objective was to determine whether aliskiren was noninferior to losartan in reducing LV mas

122 As another functional index of the effect of aliskiren, we found significant natriuresis on both diet

123 is hoped that long-term outcome studies with aliskiren will finally allow this question to be answere

124 and safety of the novel oral renin inhibitor aliskiren with placebo and an active comparator.

125 on Intravascular Ultrasound Study) comparing aliskiren with placebo in 613 participants with coronary

126 lasma renin activity (PRA) is observed after aliskiren withdrawal.

127 lockade with the direct oral renin inhibitor aliskiren would produce renal vascular responses exceedi

128 ne whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events i